Antibody Drug Development Executive/Lead/Manager

OCMS Canada Preclinical / IND-Enabling Development

Function: Antibody Drug Development Executive/Lead/Manager
Reports to: OCMS Canada CEO and OCMS Chief Operations Officer
Position: Full Time in PEI, in office with some flexibility. Office location TBD

OCMS Bio and OCMS Canada:

OCMS Bio, LLC (www.ocms.bio) is an antibody engineering company that uses a breakthrough discovery technology (tinyurl.com/OCMSVideo) to create best in class antibody drugs. Our most advanced program, OB2401, is an anti-RSV prophylactic proven in animal testing to outperform all existing alternatives. Other programs under current development target human metabolic diseases and rare diseases.

OCMS Bio, LLC is headquartered in the United States, near Philadelphia, Pennsylvania. OCMS Canada is headquartered in Prince Edward Island and represents a new business with material ownership by OCMS Bio established with a significant stake in OB2401 and investment to advance the pre-clinical development of OB2401.

Role summary:

We are looking for a highly collaborative biotech professional with project management experience and the ability to make independent decisions. The desired candidate will contribute to planning and lead execution of **late-stage preclinical and IND-enabling activities** to support regulatory submissions and the transition into clinical development. This role serves as the **central coordinator** across internal functions and external partners, ensuring timelines, budgets, quality, and regulatory readiness are met in a **resource-lean biotech environment**.

This position description is intended to describe the center of a broad range of possible hires from an experienced Chief Drug Development Officer to a Development Project Manager. Compensation and title will be commensurate with experience and responsibilities.

Key responsibilities:

Plan and drive **IND-enabling studies** across toxicology, DMPK/PK, bioanalysis, and CLD/CMC by maintaining integrated project plans, timelines, and risk registers, identifying critical path activities, and proactively mitigating risks. Coordinate activities of internal RnD

team with external vendors and consultants, including in vivo disease models, toxicology, DMPK, CMC, and regulatory, to ensure alignment between scientific strategy and operational execution. Manage CRO and vendor selection and oversight to deliver outsourced studies on time, within budget, and to quality standards, while tracking study progress and final reports. Ensure study documentation supports regulatory filings, provide clear status updates to leadership, and partner with Regulatory Affairs to support IND readiness and regulatory compliance.

Qualifications:

PhD (preferred) or MS in Life Sciences, Pharmacology, Toxicology, or a related discipline, with experience in preclinical development and/or project management within biotech or pharma, including direct support of IND-enabling programs and management of non-GLP and GLP studies. Demonstrated experience overseeing CROs and external vendors, strong project planning, organizational, and risk-management skills, excellent communication and stakeholder-management abilities, and the ability to operate effectively in a hands-on, resource-lean biotech setting with a solid understanding of regulatory expectations for preclinical development.

To Apply:

Please send cover letter and resume to phalpern@ocms.bio

OCMS Bio and OCMS Canada are equal opportunity employers. Qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, disability or any other protected categories under all applicable laws.